At the American Heart Association meeting today, Merck & Co., Inc. said it is confident in the safety and efficacy profiles of ZETIA (ezetimibe) and VYTORIN (ezetimibe/simvastatin).
Link:http://www.merck.com/newsroom/news-release-archive/product/2009_1115.html
Source:Merck